Logo Image
|Articles|April 23, 2019

Top 5 Key Takeaways from ECCMID 2019

Here are the top takeaways from the European Congress of Clinical Microbiology and Infectious Disease 2019 meeting.

ECCMID 2019 was held April 13-16, 2018, in Amsterdam, the Netherlands. The conference featured results of new studies on a variety of infectious disease and microbiology topics as well as advancements being made across the fields. Here are 5 key takeaways from the meeting.

Read more about these stories:

  • FURI Study Case: Ibrexafungerp Successfully Treats Esophageal Candidiasis
  • CAMERA2: Combination Therapy for MRSA Bacteremia Effective but Linked to Higher Mortality, AKI Rates
  • Most Patients With UTI Symptoms Receive Antibiotics, Yet Lack Evidence of Infection
  • Jose Arribas, MD, on the Challenges That Come With Long-Acting Injectables
  • ASPECT-NP: Ceftolozane/Tazobactam Efficacious for Ventilated Nosocomial Pneumonia

Related to this article

View more
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Read more
Measles Update: September 25, 2026
Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Read more
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Read more